Prime Medicine Secures $149.2M Cash Into 2027, Eyes Two IND Filings
Prime Medicine ended Q1 2026 with $149.2 million cash runway into 2027, reporting a $49.1 million net loss as R&D expenses fell to $34.1 million. The company plans IND/CTA filings for PM577 in Wilson Disease H1 2026 and PM647 mid-2026, with initial clinical data expected in 2027.
1. Financial Results
In Q1 2026, Prime Medicine reported a net loss of $49.1 million, driven by R&D expenses of $34.1 million and G&A costs of $17.4 million. Cash, cash equivalents and investments totaled $149.2 million as of March 31, 2026, providing funding into 2027.
2. Pipeline Milestones
Prime Medicine is on track to file IND and/or CTA applications for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026. The company anticipates initial clinical data from both programs in 2027.
3. Regulatory and Leadership Updates
The company continues regulatory dialogue with the FDA toward a potential BLA filing for PM359 in Chronic Granulomatous Disease. In April 2026, Svetlana Makhni was appointed Chief Financial Officer to oversee financial operations and strategy.
4. Upcoming ASGCT Presentation
Prime Medicine will present new preclinical data for its Wilson Disease program at the ASGCT Annual Meeting on May 12, 2026, detailing precise ATP7B correction and copper homeostasis restoration in disease models.